Revenue
2020
2021
2022
2023
2024
2025
Renalytix plc (RENX)
Price£0.0415Cached quote
Net income
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2019
2020
2021
2022
2023
2024
Total cash / debt
CashTotal debt
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|
| Revenue | $3.0M | $2.3M | $100,000 | $3.0M | $1.5M | $0 | — |
| Gross profit | $1.2M | $156,000 | $720,000 | $874,000 | $633,000 | $0 | — |
| Gross margin | 40.00% | 6.82% | 720.00% | 29.43% | 42.45% | — | — |
| Research & development | $900,000 | $9.3M | $14.3M | $14.6M | $10.0M | $4.6M | $4.3M |
| Operating expenses | $18.4M | $29.8M | $42.9M | $54.1M | $32.5M | $10.3M | $42.3M |
| Operating income | −$17.2M | −$29.6M | −$42.2M | −$53.2M | −$31.9M | −$10.3M | −$42.3M |
| Operating margin | −573.33% | −1,293.49% | −42,221.00% | −1,790.67% | −2,140.58% | — | — |
| EBITDA | −$21.3M | −$29.2M | −$41.7M | −$52.7M | −$31.6M | −$10.2M | −$42.3M |
| EBITDA margin | −710.00% | −1,277.59% | −41,713.00% | −1,774.21% | −2,121.66% | — | — |
| Net income | −$20.4M | −$33.5M | −$45.6M | −$45.3M | −$35.3M | −$9.8M | −$42.3M |
| Net profit margin | −680.00% | −1,461.60% | −45,607.00% | −1,524.44% | −2,369.95% | — | — |
| Basic EPSper basic share | -$0.07 | -$0.31 | -$0.55 | -$0.62 | -$0.49 | -$0.17 | -$0.99 |
| Diluted EPSper diluted share | -$0.07 | -$0.31 | -$0.55 | -$0.67 | -$0.49 | -$0.17 | -$0.99 |